Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01910168 · ClinicalTrials.gov registry record
A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis
A clinical trial of Muscular Atrophy, Spinal, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 36
- Enrollment target
- 2
- Study locations
NCT01910168 is a study of Muscular Atrophy, Spinal that has completed, run by Hoffmann-La Roche. The registered enrollment target is 36 participants, below the 73-participant average among 15 other Muscular Atrophy, Spinal trials with a reported enrollment target (51% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01910168, a study of Muscular Atrophy, Spinal, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this single center study blood samples for biomarker analysis will be collected from patients with spinal muscular atrophy. Up to 21 mL blood will be drawn from eligible patients at a single visit.
Conditions Studied
Study Locations (2)
Michigan
- - Kalamazoo
Utah
- - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01910168
The ClinicalTrials.gov registry entry for NCT01910168 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 73-participant average among 15 other Muscular Atrophy, Spinal trials with a reported enrollment target (51% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscular Atrophy, Spinal appearing as the primary indexed condition, and to 0 interventions.
NCT01910168 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Utah.
Frequently Asked Questions
What is clinical trial NCT01910168 about?
NCT01910168 is a clinical study titled "A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis". In this single center study blood samples for biomarker analysis will be collected from patients with spinal muscular atrophy. Up to 21 mL blood will be drawn from eligible patients at a single visit.
What is the current status of trial NCT01910168?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2013-08. Estimated completion is 2014-02.
What conditions does trial NCT01910168 study?
This clinical trial studies the following conditions: Muscular Atrophy, Spinal.
Who is sponsoring clinical trial NCT01910168?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01910168 being conducted?
This trial has 2 study locations across Michigan, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscular Atrophy, Spinal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
RECRUITING · Phase 2
-
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
RECRUITING · Phase 3
-
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
RECRUITING · Phase 4
-
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
RECRUITING · Phase 4
-
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
RECRUITING
-
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.